Inactivated influenza vaccine does not reduce all cause respiratory illness in children with pre-existing medical conditions.

Abstract:

BACKGROUND:The effectiveness of inactivated influenza vaccine (IIV) immunization in preventing all cause respiratory illness (RI) in children with pre-existing medical conditions has not been fully established and varies from season to season. This study aims to quantify the overall impact of IIV immunization on primary care attended RI episodes in children with pre-existing medical conditions, using robust observational data spanning twelve influenza seasons. METHODS:Electronic records of IIV eligible children aged 6 months to 18 years were extracted from primary care databases over the years 2004-2015. IIV eligibility criteria according to Dutch guidelines included (chronic) respiratory and cardiovascular disease and diabetes mellitus. For each year, information on IIV immunization status, primary care attended RI episodes (including influenza, acute respiratory tract infections and asthma exacerbations) and potential confounders were collected. Generalized estimating equations were used to model the association between IIV status and occurrence of at least one RI episode during the influenza epidemic period with "current year immunized" as reference group. Robustness of findings were assessed by performing various sensitivity analyzes in which (i) seasons with a mismatch between the dominant circulating influenza virus and vaccine strain were excluded, (ii) influenza periods were further restricted to weeks with at least 30% influenza virus positive specimens in sentinel surveillance (instead of 5%), (iii) propensity scores were used to adjust for confounding. RESULTS:In total, 11,797 children (follow-up duration: 38,701 child-years) were eligible for IIV for ≥ one season with 29% immunized at least once. The adjusted odds for primary care attended RI episodes during the influenza epidemic period did not differ between current season immunized versus not immunized children (adjusted OR:1.01; 95%CI:0.90-1.13). The various sensitivity analysis showed comparable results. CONCLUSIONS:IIV immunization in children with pre-existing medical conditions does not reduce all cause RI episodes encountered in primary care during the influenza season.

journal_name

Vaccine

journal_title

Vaccine

authors

de Hoog MLA,Venekamp RP,Meijer A,Sanders EAM,Bruijning-Verhagen PCJL

doi

10.1016/j.vaccine.2019.11.086

subject

Has Abstract

pub_date

2020-04-09 00:00:00

pages

3397-3403

issue

17

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(19)31640-8

journal_volume

38

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Immunization with recombinant paraflagellar rod protein induces protective immunity against Trypanosoma cruzi infection.

    abstract::In the present study, we have produced recombinant paraflagellar rod proteins (PFR) and report their use for successful vaccination of mice against Trypanosoma cruzi. This protection is associated with a highly polarized type 1 cytokine production profile. Additionally, we have analyzed the gene sequence encoding PFR-...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00108-7

    authors: Luhrs KA,Fouts DL,Manning JE

    更新日期:2003-06-20 00:00:00

  • Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.

    abstract::A highly efficacious vaccine is required to counteract a threat of an avian influenza pandemic. Increasing the potency of vaccines by adjuvation is essential not only to overcome generally low immunogenicity of pandemic strains, but also to allow dose sparing and as such to make it feasible to satisfy huge global prod...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.04.071

    authors: Radosević K,Rodriguez A,Mintardjo R,Tax D,Bengtsson KL,Thompson C,Zambon M,Weverling GJ,Uytdehaag F,Goudsmit J

    更新日期:2008-07-04 00:00:00

  • Use of rubella seroepidemiological data for assessment of previous vaccination policy and for decision making in response to epidemics in Israel.

    abstract::We examined the prevalence of rubella antibodies in a representative sample of the Israeli population. Three thousand three hundred and twenty-six sera collected during 1997 and 1998, from an age-stratified general population sample were tested for specific IgG antibodies against rubella. The sero-positivity rates to ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.024

    authors: Cohen D,Muhsen Kh,Aboudy Y,Harari H,Mendelson E,Green MS

    更新日期:2006-07-07 00:00:00

  • Beta-propiolactone treatment impairs the biological activity of residual DNA from BHK-21 cells infected with rabies virus.

    abstract::The effects of beta-propiolactone (BPL), an alkylating and virus inactivating agent, on the structural and in vitro biological properties of different DNA preparations from BHK-21 cells were investigated. Both uninfected and rabies virus-infected cells were used. Purified cellular DNA (celDNA) was used as the referenc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90343-v

    authors: Morgeaux S,Tordo N,Gontier C,Perrin P

    更新日期:1993-01-01 00:00:00

  • Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge.

    abstract::The stockpiling of live vaccinia virus vaccines has enhanced biopreparedness against the intentional or accidental release of smallpox. Ongoing research on future generation smallpox vaccines is providing key insights into protective immune responses as well as important information about subunit-vaccine design strate...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.11.007

    authors: Xiao Y,Zeng Y,Alexander E,Mehta S,Joshi SB,Buchman GW,Volkin DB,Middaugh CR,Isaacs SN

    更新日期:2013-01-02 00:00:00

  • Report from Working Group 3 (the Czech Republic, Denmark, Finland, Norway, The Netherlands, Slovakia, Sweden and the UK).

    abstract::The Czech Republic, Denmark, Finland, Norway, the Netherlands, Slovakia, Sweden and the UK all have very low HBsAg carrier rates; in the Scandinavian countries, for instance, carrier rates are on the order of 0.05%. Most countries in this group are unconvinced that the carrier rates and the burden of disease caused by...

    journal_title:Vaccine

    pub_type:

    doi:10.1016/s0264-410x(98)00299-0

    authors: Iwarson S

    更新日期:1998-11-01 00:00:00

  • Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.

    abstract:BACKGROUND:China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2012.11.051

    authors: Guo B,Page A,Wang H,Taylor R,McIntyre P

    更新日期:2013-01-11 00:00:00

  • Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation.

    abstract::Recent findings in the interactions between pathogens and the innate immune system, particularly with dendritic cells (DC), have opened new opportunities for adjuvants designs. We have elaborated a new approach, in which gangliosides are incorporated into the outer membrane complex of Neisseria meningitidis to form ve...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.01.114

    authors: Mesa C,de León J,Rigley K,Fernández LE

    更新日期:2006-04-12 00:00:00

  • Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

    abstract:BACKGROUND:Gram-negative bacteria (GNB) are a leading cause of nosocomial infection and sepsis. Increasing multi-antibiotic resistance has left clinicians with fewer therapeutic options. Antibodies to GNB lipopolysaccharide (LPS, or endotoxin) have reduced morbidity and mortality as a result of infection and are not su...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.10.072

    authors: Cross AS,Greenberg N,Billington M,Zhang L,DeFilippi C,May RC,Bajwa KK

    更新日期:2015-11-27 00:00:00

  • Delivery of antigen to sialoadhesin or CD163 improves the specific immune response in pigs.

    abstract::Delivery of antigens to antigen presenting cell surface receptors represents a promising strategy to improve immune response to weak immunogenic antigens. We have analyzed the potential of porcine sialoadhesin (Sn) and CD163 as antigen targeting receptors using mouse Igs as surrogate antigens. Sn and CD163 are two end...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.04.076

    authors: Poderoso T,Martínez P,Álvarez B,Handler A,Moreno S,Alonso F,Ezquerra Á,Domínguez J,Revilla C

    更新日期:2011-06-24 00:00:00

  • A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults.

    abstract::Epidemic influenza occurs annually throughout the world and is accompanied by excess morbidity and mortality. Increasing the antigen content and topical administration of vaccine are two strategies being explored to improve the immune responses to trivalent inactivated influenza vaccine (TIV). We conducted a randomize...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2007.05.002

    authors: Atmar RL,Keitel WA,Cate TR,Munoz FM,Ruben F,Couch RB

    更新日期:2007-07-20 00:00:00

  • Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

    abstract:BACKGROUND:Shigellae cause severe disease in endemic countries, especially in children. Several efficacy trials have been conducted with candidate vaccines against Shigellae, but the lack of protection, the safety concerns, or manufacturing challenges hindered successful market approval. Conjugated vaccines have been s...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2015.06.102

    authors: Hatz CF,Bally B,Rohrer S,Steffen R,Kramme S,Siegrist CA,Wacker M,Alaimo C,Fonck VG

    更新日期:2015-08-26 00:00:00

  • Immunization with pneumococcal elongation factor Tu enhances serotype-independent protection against Streptococcus pneumoniae infection.

    abstract::Vaccination is an effective strategy to prevent pneumococcal diseases. Currently, licensed vaccines include the pneumococcal polysaccharide vaccine (PPSV) and the pneumococcal conjugate vaccine (PCV), which target some of the most common of the 94 serotypes of S. pneumoniae based on their capsular composition. However...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.11.015

    authors: Nagai K,Domon H,Maekawa T,Hiyoshi T,Tamura H,Yonezawa D,Habuka R,Saitoh A,Terao Y

    更新日期:2019-01-03 00:00:00

  • Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert.

    abstract::A recombinant fowlpox vaccine with an H5 hemagglutinin gene insert protected chickens against clinical signs and death following challenge by nine different highly pathogenic H5 avian influenza viruses. The challenge viruses had 87.3 to 100% deduced hemagglutinin amino acid sequence similarity with the recombinant vac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00369-2

    authors: Swayne DE,Garcia M,Beck JR,Kinney N,Suarez DL

    更新日期:2000-01-06 00:00:00

  • Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults

    abstract::The annual contact for influenza vaccination provides an opportunity to ensure that adults have received other recommended vaccines such as Tdap. Healthy 19-64 year-olds were randomized to receive concomitant administration of Tdap and influenza vaccines or influenza vaccine followed (in 4-6 weeks by) Tdap. 720 partic...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2006.12.047

    authors: McNeil SA,Noya F,Dionne M,Predy G,Meekison W,Ojah C,Ferro S,Mills EL,Langley JM,Halperin SA

    更新日期:2007-04-30 00:00:00

  • Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.

    abstract:BACKGROUND:Development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production is a high priority. We conducted this study to determine the protective efficacy a recombinant, baculovirus-expressed seasonal trivalent influenza virus hemagglutinin (rHA0) vaccine (FluBlok(®)). METHO...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2011.07.128

    authors: Treanor JJ,El Sahly H,King J,Graham I,Izikson R,Kohberger R,Patriarca P,Cox M

    更新日期:2011-10-13 00:00:00

  • A randomized, placebo-controlled study of oral cimetidine as an immunopotentiator of parenteral immunization with a group B meningococcal vaccine.

    abstract::Cimetidine (CIM) is an H2-receptor antagonist with a long history of clinical use in peptic ulcer disease. In addition to its inhibitory effect upon gastric acid secretion, CIM can also block histamine-mediated immunosuppression by inhibiting H2 receptors on suppressor T cells. CIM results in immunoaugmentation of bot...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0264-410x(96)00311-8

    authors: Drabick JJ,Tang DB,Moran EE,Trofa AF,Foster JS,Zollinger WD

    更新日期:1997-07-01 00:00:00

  • Rescue of a vaccine strain of peste des petits ruminants virus: In vivo evaluation and comparison with standard vaccine.

    abstract::Across the developing world peste des petits ruminants virus places a huge disease burden on agriculture, primarily affecting the production of small ruminant. The disease is most effectively controlled by vaccinating sheep and goats with live attenuated vaccines that provide lifelong immunity. However, the current va...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.10.050

    authors: Muniraju M,Mahapatra M,Buczkowski H,Batten C,Banyard AC,Parida S

    更新日期:2015-01-09 00:00:00

  • New vaccine introductions in Africa before and during the decade of vaccines - Are we making progress?

    abstract::Vaccines are excellent investments with far-reaching rewards beyond individual and population health, but their introduction into national programs has been historically slow in Africa. We provide an overview of the introduction of new and underutilized vaccines in countries of the WHO African Region by 2017, using da...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.05.002

    authors: Sambala EZ,Wiyeh AB,Ngcobo N,Machingaidze S,Wiysonge CS

    更新日期:2019-05-31 00:00:00

  • Sudden infant death syndrome (SIDS): are common bacterial toxins responsible, and do they have a vaccine potential?

    abstract::Despite extensive research, no unifying concept has satisfactorily explained the cause of the sudden infant death syndrome (SIDS). The details are briefly outlined of some of the evidence supporting the hypothesis that common bacterial toxins are important in the aetiology of SIDS. These bacterial toxins act as trigge...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/0264-410x(94)90102-3

    authors: Murrell TG,Murrell WG,Lindsay JA

    更新日期:1994-03-01 00:00:00

  • Vaccines and the regulatory arm of the immune system. An overview from the Trypanosoma cruzi infection model.

    abstract::The knowledge that the immune system is composed of a regulatory/suppressor arm added a new point of view to better understand the nature of several pathologies including cancer, transplants, infections and autoimmune diseases. The striking discoveries concerning molecules and cells involved in this kind of regulation...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2019.05.015

    authors: Cabrera G,Marcipar I

    更新日期:2019-06-19 00:00:00

  • Indicators to assess National Immunization Technical Advisory Groups (NITAGs).

    abstract::A National Immunization Technical Advisory Group (NITAG) is an expert advisory committee that provides evidence-based recommendations to the Ministry of Health (MoH) to guide immunization programs and policies. The World Health Organization (WHO), the Initiative for Supporting National Independent Immunization and Vac...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.01.047

    authors: Blau J,Sadr-Azodi N,Clementz M,Abeysinghe N,Cakmak N,Duclos P,Janusz C,Jauregui B,Mihigo R,Mosina L,Takashima Y,Senouci K

    更新日期:2013-05-28 00:00:00

  • Large-scale influenza vaccination promotion on a mobile app platform: A randomized controlled trial.

    abstract::While health-care providers have used incentives in an attempt to motivate patients to obtain vaccinations, their effect on vaccination rates has not been systematically evaluated on a large scale. In this study, we examined whether mobile applications may improve population vaccination rates through enhanced communic...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.11.053

    authors: Lee WN,Stück D,Konty K,Rivers C,Brown CR,Zbikowski SM,Foschini L

    更新日期:2020-04-16 00:00:00

  • Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus.

    abstract::A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). In this study, CPMV-PARVO1 was inactivated by UV tre...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00083-4

    authors: Langeveld JP,Brennan FR,Martínez-Torrecuadrada JL,Jones TD,Boshuizen RS,Vela C,Casal JI,Kamstrup S,Dalsgaard K,Meloen RH,Bendig MM,Hamilton WD

    更新日期:2001-06-14 00:00:00

  • Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients.

    abstract:BACKGROUND:Several vaccines are recommended in HIV-infected patients due to an increased risk of vaccine-preventable infections, severe forms of the disease, or shared transmission routes. Few data are available regarding vaccination coverage and its determinants in this population. METHODS:A cross-sectional study was...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.015

    authors: Valour F,Cotte L,Voirin N,Godinot M,Ader F,Ferry T,Vanhems P,Chidiac C

    更新日期:2014-07-31 00:00:00

  • Epitope-specific cytotoxic T lymphocyte induction by minigene DNA immunization.

    abstract::Plasmid DNA vaccines encoding full-length antigen often induce both potent antibody and cytotoxic T lymphocyte (CTL) responses. Here, we examine strategies to exclusively elicit epitope-specific CTL responses using DNA constructs expressing a minimal class I MHC-restricted epitope of the nucleoprotein (NP) of influenz...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00411-3

    authors: Iwasaki A,Dela Cruz CS,Young AR,Barber BH

    更新日期:1999-04-09 00:00:00

  • Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.

    abstract::In this study, the impact of Th1-inducing cytokine gene co-delivery and antigen boosting on humoral and cellular responses induced by multiepitopic DNA immunization in mice have been investigated. Intramuscular injection of mixed DNA constructs encoding for HIV-1 Gag, Tat and Nef proteins, co-administered with the DNA...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(01)00004-4

    authors: Billaut-Mulot O,Idziorek T,Loyens M,Capron A,Bahr GM

    更新日期:2001-04-06 00:00:00

  • High immunogenicity of delayed third dose of hepatitis B vaccine in travellers.

    abstract::Travellers often present late for the third dose of hepatitis B vaccination and measuring anti-HBs serology is common practice to ensure that these individuals are protected. We assessed the adequacy of immune response in 86 healthy travellers who had their third dose of hepatitis B (HB) vaccine performed more than 1 ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.12.053

    authors: Jackson Y,Chappuis F,Mezger N,Kanappa K,Loutan L

    更新日期:2007-04-30 00:00:00

  • The first safe inactivated equine influenza vaccine formulation adjuvanted with ISCOM-Matrix that closes the immunity gap.

    abstract::Equine influenza is a contagious diseases caused by equine influenza viruses which belong to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently competition horses are required to be regularly vaccinated against equine influenza. Currently availab...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.06.085

    authors: Heldens JG,Pouwels HG,Derks CG,Van de Zande SM,Hoeijmakers MJ

    更新日期:2009-09-04 00:00:00

  • The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.

    abstract::We investigated the influence of the site of administration of DNA vaccine on the induced immune response. DNA vaccines were administered by electroporation at three different sites: tibial cranial muscle, abdominal skin and ear pinna. Aiming to draw general conclusions about DNA vaccine delivery, we successively used...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.05.005

    authors: Vandermeulen G,Vanvarenberg K,De Beuckelaer A,De Koker S,Lambricht L,Uyttenhove C,Reschner A,Vanderplasschen A,Grooten J,Préat V

    更新日期:2015-06-22 00:00:00